<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743923</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT 22</org_study_id>
    <nct_id>NCT02743923</nct_id>
  </id_info>
  <brief_title>Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer</brief_title>
  <official_title>Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Society of Physicians for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether carboplatin-paclitaxel-bevacizumab results
      in a prolonged progression free survival compared to cisplatin-pemetrexed as first line
      treatment in patients with KRAS mutated non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KRAS mutations occur in 30% of patients with non-small cell lung cancer, especially
      adenocarcinoma. For long time KRAS mutation has been related with poor prognosis and poor
      response to chemotherapy. Recent data however show that this is both not true. It seems that
      response, progression free survival and overall survival is similar in KRAS mutated. Until
      now no specific targeted therapy is available for KRAS mutated NSCLC patients. Optimization
      of treatment in advanced NSCLC patients with a KRAS mutation could also be achieved by
      selecting the best available chemotherapy treatment.

      Two standard chemotherapy schemes are frequently used and FDA and EMA approved as first line
      treatment for patients with adenocarcinoma: cisplatin-pemetrexed and
      carboplatin-paclitaxel-bevacizumab.

      The aim of this randomized phase III study is to compare two standard treatment regimens in
      patients with KRAS mutated, advanced stage NSCLC and the hypothesis is that bevacizumab with
      chemotherapy improves outcomes compared to chemotherapy alone as first line treatment.
      Furthermore the outcome for the different KRAS mutations will be studied.

      Treatment with one of the two following chemotherapy combinations according to the label:
      carboplatin-paclitaxel-bevacizumab or cisplatin-pemetrexed q3wks for up to six cycles.
      Continuation maintenance with bevacizumab and pemetrexed is allowed until progression. Blood
      and archival tissue will be optionally collected for translational research. This may help to
      identify subgroups of patients who are likely better treated with a specific treatment
      regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>Every 6 weeks, from date of randomization until the date of progression of disease or of death from any cause, assessed up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>Every 6 weeks, from date of randomization until the date of progression of disease or of death from any cause, assessed up to 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>date of randomization to the date of death from any cause, assessed up to 60 months.</time_frame>
    <description>Stratification for KRAS mutation (G12V versus G12C versus other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>outcome between G12V versus G12C versus other subtypes of KRAS mutations (mutational analysis on plasma and blood platelets).</measure>
    <time_frame>date of randomization to the date of death from any cause, assessed up to 60 months.</time_frame>
    <description>The two most common KRAS types are G12C in about 40% of cases, G12V in 18% and G12D in 15% of cases. Subgroup analyses are planned to explore treatment effect in these different KRAS mutations groups. At baseline the metastatic patterns of these subgroups will be described. KRAS mutations in NSCLC occur mainly in codon 12 and 13.
Stratification for KRAS mutation (G12V versus G12C versus other) at randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response by Crabb criteria (if applicable)</measure>
    <time_frame>Every 6 weeks, from date of randomization until the date of progression of disease or of death from any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>carboplatin-paclitaxel- bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin-pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 6</description>
    <arm_group_label>carboplatin-paclitaxel- bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>200mg/m2</description>
    <arm_group_label>carboplatin-paclitaxel- bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg</description>
    <arm_group_label>carboplatin-paclitaxel- bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2</description>
    <arm_group_label>cisplatin-pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>75 mg/m2</description>
    <arm_group_label>cisplatin-pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed (non-squamous) NSCLC incurable locally
             advanced or metastatic (stage IIIB and stage IV) disease.

          2. Documented KRAS mutation

          3. Chemotherapy-naive NSCLC patients. Adjuvant chemotherapy or chemoradiotherapy is
             allowed when given &gt; 1 year for study entry. Previous anti-PD(L1) therapy for advanced
             disease is allowed.

          4. At least one unidimensionally measurable lesion meeting RECIST1.1.

          5. ECOG PS 0-2

          6. Age ≥ 18 years

          7. Adequate organ function, including:

               -  Adequate bone marrow reserve: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L.

               -  Hepatic: bilirubin ≤1.5 x ULN, AP, ALT, AST ≤ 3.0 x ULN AP, ALT, and AST ≤5 xULN
                  is acceptable if the liver has tumor involvement

               -  Renal: calculated creatinine clearance ≥ 60 ml/min based on the Cockroft-Gault
                  formula.

               -  Urine protein (dip-stick) &lt; 2 +; when ≥ 2 +: 24 hours urine protein ≤ 1 gr.

          8. Signed informed consent

          9. Male and female patients with reproductive potential must use an approved
             contraceptive method, if appropriate. Female patients with childbearing potential must
             have a negative serum pregnancy test within 7 days prior to study enrollment.

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Clinically significant (i.e. active) cardiovascular disease: congestive heart failure
             &gt;NYHA class 2; CVA or myocardial infarction &lt; 6 months prior to study entry;
             uncontrolled hypertension (blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 100
             mmHg)

          3. History of hemoptysis ≥ grade 2 (bright red blood of at least 2,5 ml in the last 3
             months)

          4. Evidence of tumor invading major blood vessels on imaging (i.e. superior vena cava or
             pulmonary artery)

          5. Patients with evidence or history of bleeding diathesis

          6. Non-healing wound or ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie C Dingemans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dutch Society of Physicians for Pulmonology and Tuberculosis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Marie C Dingemans, MD PhD</last_name>
    <phone>+31 433875047</phone>
    <email>a.dingemans@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A J de Langen, MD PhD</last_name>
    <phone>+31 205122958</phone>
    <email>j.d.langen@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VUmc Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idris Bahce, MD</last_name>
      <email>i.bahce@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Idris Bahce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Schouwink, MD</last_name>
      <email>J.Schouwink@mst.nl</email>
    </contact>
    <investigator>
      <last_name>Hugo Schouwink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joop van den Brand, MD</last_name>
      <email>JJG.vanden.Brand@meandermc.nl</email>
    </contact>
    <investigator>
      <last_name>Joop van den Brand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Welling, MD</last_name>
    </contact>
    <contact_backup>
      <email>a.welling@mca.nl</email>
    </contact_backup>
    <investigator>
      <last_name>A Welling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZGT</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeske Staal, MD</last_name>
      <email>j.staal@zgt.nl</email>
    </contact>
    <investigator>
      <last_name>Jeske Staal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egbert Smit</last_name>
      <email>e.smit@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Egbert Smit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Moons, MD</last_name>
      <email>A.Moons-Pasic@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>A Moons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Pronk, MD</last_name>
      <email>n.pronk@gelre.nl</email>
    </contact>
    <investigator>
      <last_name>Niels Pronk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaas van Walree, MD</last_name>
      <email>nwalree@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Nicolaas van Walree, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonne Biesma, MD</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pepijn Brocken, MD</last_name>
      <email>p.brocken@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Pepijn Brocken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzy Samii, MD</last_name>
      <email>s.samii@dz.nl</email>
    </contact>
    <investigator>
      <last_name>Suzy Samii, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric van Thiel, MD</last_name>
      <email>EricvanThiel@asz.nl</email>
    </contact>
    <investigator>
      <last_name>Eric van Thiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisanne Kastelijn, MD</last_name>
      <email>kastelijnl@zgv.nl</email>
    </contact>
    <investigator>
      <last_name>Lisanne Kastelijn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjen van Henten, MD</last_name>
      <email>a.vanhenten@mmc.nl</email>
    </contact>
    <investigator>
      <last_name>Arjen van Henten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Groen, MD</last_name>
      <email>h.j.m.groen@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Harry Groen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John van Putten, MD</last_name>
      <email>jwg.van.putten@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>John van Putten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi ziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Maarten van Haarst, MD</last_name>
      <email>jvanhaarst@tergooi.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Maarten van Haarst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2130 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frans Krouwels, MD</last_name>
      <email>fkrouwels@spaarnegasthuis.nl</email>
    </contact>
    <investigator>
      <last_name>Frans Krouwels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venmans, MD</last_name>
    </contact>
    <investigator>
      <last_name>Venmans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Dingemans, MD</last_name>
      <email>a.dingemans@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Dingemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3007 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan van 't Westeinde, MD</last_name>
      <email>westeindes@maasstadziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Susan van 't Westeinde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Fransicus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wessel Hanselaar, MD</last_name>
      <email>w.hanselaar@franciscus.nl</email>
    </contact>
    <investigator>
      <last_name>Wessel Hanselaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Haaglanden</name>
      <address>
        <city>the Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaar Maas, MD</last_name>
      <email>k.maas@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>Klaar Maas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leontine van Elden, MD</last_name>
      <email>lvelden@diakhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Leontine van Elden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Schramel, MD</last_name>
      <email>f.schramel@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Franz Schramel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian van Kampen, MD</last_name>
      <email>vvankampen@viecuri.nl</email>
    </contact>
    <investigator>
      <last_name>Vivian van Kampen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Stigt</last_name>
      <email>j.a.stigt@isala.nl</email>
    </contact>
    <investigator>
      <last_name>Jos Stigt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

